Comparative Pharmacology
Head-to-head clinical analysis: LESCOL versus PRAVACHOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LESCOL versus PRAVACHOL.
LESCOL vs PRAVACHOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to increased LDL receptor expression and reduced plasma LDL cholesterol.
Competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to increased hepatic LDL receptor expression and reduced plasma LDL cholesterol.
For primary hypercholesterolemia: starting dose 20 mg orally once daily, titrated to a maximum of 80 mg once daily. For patients requiring LDL-C reduction >25%, start at 40 mg once daily. For prevention of cardiovascular events: 40 mg orally once daily.
10-80 mg orally once daily, with or without food, typically in the evening.
None Documented
None Documented
Terminal elimination half-life is 2.5 to 4.0 hours; clinical context: effective for once-daily dosing due to prolonged HMG-CoA reductase inhibition despite short half-life.
The terminal elimination half-life of pravastatin is approximately 1.8 hours, but clinical LDL-cholesterol lowering effects persist beyond this due to sustained HMG-CoA reductase inhibition.
Primarily biliary, with approximately 90% recovered in feces as parent drug and metabolites; renal excretion accounts for less than 10%.
Approximately 70% of an oral dose is excreted in feces, primarily as metabolites, with about 20% recovered in urine. Biliary excretion is a major route for parent drug and metabolites.
Category C
Category C
HMG-CoA Reductase Inhibitor
HMG-CoA Reductase Inhibitor